ETRM EnteroMedics Inc. featured news, full reports, and detailed charts
EnteroMedics Inc. (ETRM) Wrap Up:
This Annual Report on Form 10-K contains forward-looking statements. These forward-looking statements are based on our current expectations about our business and industry. In some cases, these statements may be identified by terminology such as “may,” “will”, “should,” “expects,” “could,” “intends,” “might,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of such terms and other comparable terminology. These statements involve known and unknown risks and uncertainties that may cause our results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Factors that may cause or contribute to such differences include, among others, those discussed in this report in Item 1A “Risk Factors.” Except as may be required by law, we undertake no obligation to update any forward-looking statement to reflect events after the date of this report. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f13%2f0001193125-08-055244.html#FIS_BUSINESS"EnteroMedics, Inc. (ETRM*(D):NASDAQ)
Snapshot of EnteroMedics, Inc. (ETRM)
|
OPEN
$0.60
|
PREVIOUS CLOSE
$0.61
|
|
|
DAY HIGH
$0.62
|
DAY LOW
$0.53
|
|
|
52 WEEK HIGH
09/29/09 - $5.58
|
52 WEEK LOW
10/28/09 - $0.50
|
|
|
MARKET CAP
22.1M
|
AVERAGE VOLUME 3 mo
532.3K
|
|
|
DILUTED EPS TTM
$-1.51
|
SHARES OUTSTANDING
37.4M
|
|
|
ETRM Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ETRM Top Compensated Officers
Executives, Board Directors
Key developments for EnteroMedics, Inc. (ETRM)
EnteroMedics Inc. announced preliminary findings from its ongoing detailed review of its EMPOWER(TM) study, a randomized, double-blind, controlled pivotal study designed to evaluate the safety and efficacy of the Maestro(R) System in the treatment of obesity. On October 2, 2009, the company announced that the study did not meet its primary and secondary efficacy endpoints, as results in the control and treatment arms were statistically indistinguishable, while achieving all of its safety endpoints. The ongoing detailed review suggests that vagal blocking therapy may promote safe and effective weight loss as an adjunct to behavioral support, diet and exercise in morbidly obese patients. The review further suggests that these effects were evident in both the treatment and control arms. The company is continuing a comprehensive analysis of all clinical, statistical, and engineering data to understand this finding. Based on the analysis to date, the control arm of the trial, which was intended to be inactive, apparently provided a low-intensity blocking signal that introduced VBLOC Therapy in human subjects.
To discuss the detailed findings of its EMPOWER study
EnteroMedics Inc. announced that it has implemented a plan to reduce its workforce and operating costs in order to preserve capital and streamline its operations following the announcement of top-line results from its pivotal EMPOWER study on October 2, 2009. The reduction in force will lower the number of employees by 40%, to a total of 33, by November 15, 2009. The reduction in force is expected to result in approximately $3.2 million in reduced operating expenses in 2010.
ETRM Competitors
| Company | Last | Change | |
| No competitor information is available for ETRM. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | ETRM | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 5.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ETRM |
||
ETRM transactions
| Type Date |
Target |
|
Private Placement
October 2, 2009 |
-- |